Chronic exposure to anabolic steroids induces the muscle expression of oxytocin and a more than fiftyfold increase in circulating oxytocin in cattle. Molecular mechanisms in skeletal muscle associated with anabolic steroid treatment of cattle are unclear and we aimed to characterize transcriptional changes. Cattle were chronically exposed (68 Ϯ 20 days) to a steroid hormone implant containing 200 mg trenbolone acetate and 20 mg estradiol (Revalor-H). Biopsy samples from 48 cattle (half treated) from longissimus dorsi (LD) muscle under local anesthesia were collected. Gene expression levels were profiled by microarray, covering 16,944 unique bovine genes: 121 genes were differentially expressed (DE) due to the implant (99.99% posterior probability of not being false positives). Among DE genes, a decrease in expression of a number of fat metabolism-associated genes, likely reflecting the lipid storage activity of intramuscular adipocytes, was observed. The expression of IGF1 and genes related to the extracellular matrix, slow twitch fibers, and cell cycle (including SOX8, a satellite cell marker) was increased in the treated muscle. Unexpectedly, a very large 21-(microarray) to 97 (real time quantitative PCR)-fold higher expression of the mRNA encoding the neuropeptide hormone oxytocin was observed in treated muscle. We also observed an ϳ50-fold higher level of circulating oxytocin in the plasma of treated animals at the time of biopsy. Using a coexpression network strategy OXTR was identified as more likely than IGF1R to be a major mediator of the muscle response to Revalor-H. A re-investigation of in vivo cattle LD muscle samples during early to mid-fetal development identified a Ͼ128-fold increased expression of OXT, coincident with myofiber differentiation and fusion. We propose that oxytocin may be involved in mediating the anabolic effects of Revalor-H treatment.
WHEN CONSIDERED AS a single tissue, skeletal muscle makes up 50% of the mass of most mammals and contributes 25% to basal energy expenditure (19) . Consequently, in addition to locomotor performance, muscle growth rate has a major influence on the metabolic efficiency of the whole animal. This is of particular interest to those industries whose primary focus is on the efficient production of muscle, such as the beef industry. Sex steroids are widely used in some parts of the beef industry to increase yield and efficiency of growth (22) . There are multiple lines of evidence linking the sex steroids, testosterone and estrogen, to increased muscle mass in mammals. For example, human sexual dimorphism in muscle mass emerges during late puberty, coincident with a surge of endogenous testosterone in males. Similarly, hypogonadal men who produce lower levels of endogenous testosterone have reduced muscle mass compared with their eugonadal counterparts (62) . Exogenous administration of both testosterone (4) and estrogen (11) influences muscle phenotype in humans. Supraphysiologic doses of androgens have been core components of doping programs in elite power sports for decades. Testosterone has been shown to induce muscle hypertrophy and lead to increases in voluntary strength (50) . Estrogen has been shown to stimulate muscle repair and regenerative processes (11) , although the extent and direction of the muscle response does seem contingent on species and circumstance (23, 28, 33) .
Because final muscle fiber number is set prior to birth in most mammals, postnatal muscle growth normally occurs by hypertrophy of existing fibers. In order for these existing fibers to expand, they require additional nuclear material. In many instances of adult muscle growth and regeneration, the additional nuclear material is supplied by a population of normally quiescent satellite cells that lie outside the myofibers. Notable exceptions to this observation include the myostatin blockade, which is initially independent of satellite cell activation (3) . Nevertheless, proliferation of satellite cells is activated by sex steroid treatment and is thought to contribute to steroid induced muscle growth (50, 11) .
In broad terms, the mechanism by which sex steroids mediate their growth promotant effect is thought to be both direct, i.e., by binding to the androgen and estrogen receptors expressed by muscle itself, and also indirect, by inducing other circulating growth promoting substances that then secondarily stimulate muscle growth. Evidence for direct action includes the fact that exogenous steroids elicit an allometric pattern of muscle growth in line with androgen and estrogen receptor density, with the more dramatic phenotype in muscles with higher sex steroid receptor densities (47) . Evidence for indirect action comes from the observed induction of other known anabolic agents following steroid treatment. For example, treatment of soleus, a predominantly slow twitch muscle, from aged castrated rat, with 5␣-dihydrotestosterone induces IGF1 and the IGF1 splice variant mechano-growth factor within 24 h, leading to a molecular switch to a more type II muscle phenotype (13) . Similarly, treatment of young castrated cattle with estradiol-17␤ increases the levels of growth hormone (GH) and IGF1 in plasma (5) .
Despite this range of evidence, the exact molecular mechanism(s) through which sex steroids exert their growth promotant effect has not been fully delineated. The use of different mammalian models, different time frames, different muscles, in vitro as well as in vivo circumstances, different combinations of treatments, and different downstream assays has undoubtedly confounded interpretation. Here, we aim to fill in some of this molecular detail by examining the combined impact of the slow release, synthetic highly androgenic trenbolone acetate and the estrogenic estradiol on an epaxial skeletal muscle in cattle.
At a time when the increase in muscle mass had already become apparent, we interrogated high-throughput gene expression data from muscle samples using two recently published coexpression-based network inference approaches called partial correlation coefficient with information theory (43) and regulatory impact factor (RIF) (20) and the promoter structure of the differentially expressed (DE) genes. Our results point to a dramatic and unexpected induction of muscle oxytocin (OXT) expression also measurable in the plasma at the protein level. We hypothesize that the increased expression of OXT may account for the increased muscle mass.
MATERIALS AND METHODS
Ethics approval. All animal procedures in this study were approved by the New South Wales (NSW) Department of Primary Industries Orange Agricultural Institute Animal Ethics Committee (approval numbers ORA/06/001 and ORA 06/004), Commonwealth Scientific and Industrial Research Organisation (CSIRO) Rockhampton Animal Experimentation Ethics Committee (approval number RH216-06), and the Department of Agriculture and Food, Western Australia (WA) Animal Ethics Committee (approval number 2-06-11).
Animals and RNA samples. The cattle used for this study were a subset from a larger study conducted at two sites with a hormone growth promotant (HGP) overlay. Some carcass data, intramuscular fat percentage (IMF), and average daily gain (ADG) are available in Table 1 , where IMF was 1.8 Ϯ 0.7 and 1.8 Ϯ 0.6, for HGP-treated and untreated cattle, respectively. The ADG for the two groups was 1.4 Ϯ 0.3 for HGP-treated and 0.9 Ϯ 0.3 for the untreated cattle. Full experimental details on the larger study were provided previously (7, 8) . In brief, at the NSW site the cattle were fed on pasture for 6 mo and grain fed at a feedlot for 117 days. At the WA site the cattle were fed on pasture for 8 mo and grain fed at a feedlot for 80 days. Two weeks after feedlot entry half the animals from each site received one dose of Revalor-H (Virbac, Milperra, NSW, Australia), a hormonal growth promotant consisting of 200 mg trenbolone acetate and 20 mg 17␤-estradiol. Each dose of 10 small slow-release pellets was implanted with an applicator gun in the ear subcutaneously (between the skin and cartilage) on the back of the middle third of the ear, not penetrating the cartilage. For the present study, 48 biopsy samples (ϳ1 g) were collected from the LD muscle, over the 13th rib under local anesthesia, 87-88 days for NSW and 48 -49 days for WA after HGP implantation, respectively. The muscle samples were immersed in RNAlater (Ambion) and frozen following manufacturer's protocols. In brief, samples immersed in RNA later were incubated overnight at 4°C and then transferred to Ϫ20°C, and no fixing was done. Samples were stored for 16 and 18 mo, respectively, for NSW and WA sites before RNA extraction was done.
Plasma OXT. Plasma OXT was measured on 12 steers from the larger study. Four out of six nontreated and one out of six treated animals were included in the array study. Six steers had received the Revalor-H implant 65 days prior, and six had not. Blood samples were collected through coccygeal venipuncture into EDTA vacutainers (BD, Plymouth, UK) and plasma stored at Ϫ20°C until analysis. OXT was measured using the EIA kit developed by Assay Designs (Ann Arbor, MI). The intra-assay variation is 9 -12% coefficient of variation (CV) and interassay variation is 5-15% CV (calculated by a 4-parameter logistic curve fitting). Assay designs reported a minimum detection limit of 5 pg/ml. The cross-reactivity of the OXT assay with vasopressin is very low (0.6%). Peptides were extracted from 0.3 ml plasma samples using SepPak (Millipore) C18 columns before analysis. The columns were preconditioned with 1 ml acetonitrile and 0.6 ml samples [0.3 ml plasma and 0.3 ml 0.1% trifluoroacetic acid (TFA)] were applied to the columns. The columns were washed with 20 ml of 0.1% TFA, and the peptides were eluted by 3 ml of acetonitrile: 0.1% TFA (60:40) and evaporated to dryness on a Savant Speed Vac and one-half of the samples reconstituted in 0.2 ml of assay buffer. The absorbance was read using a SpectraMax Plus (Molecular Devices). Included on each plate were standards and controls, as recommended by the manufacturer. The color development of the samples was read at 450 nm, with background corrected at 580 nm. The SOFTmaxPro software was used for creation of standard curves, curve fitting, and calculation of concentrations.
Total RNA extraction. The tissue sample was removed from the RNAlater solution and patted dry with tissue. Following the trimming of subcutaneous fat from muscle biopsies, total RNA was extracted using TRIzol (Invitrogen, Carlsbad, CA). In brief, samples were frozen in liquid nitrogen, then smashed with a hammer into a powder, mixed with TRIzol reagent, and homogenized using a Ultraturrax machine (IKA, Janke & Kunkel) for 15 s. Following a 5 min incubation, the sample was centrifuged at 3,900 rpm for 5 min. The supernatant was transferred to a new tube to which chloroform was added and mixed by vigorous shaking. This was incubated for 3 min and then centrifuged at 12,000 rpm for 10 min. The top phase containing the total RNA was carefully transferred into a new tube, and Qiagen RLT lysis buffer and ethanol was added. The tube was inverted five times and applied to an RNeasy (Qiagen) column. The column was centrifuged for 10,000 rpm for 30 s, discarding the flow through. Wash (RW1) buffer was added to the column, which was centrifuged at 8,000 rpm for 30 s. Sample was DNase I (Ambion, Austin, TX) treated by applying 80 l DNase treatment (10 l DNase stock ϩ70 l buffer RDD) onto column and incubating for 15 min. RW1 buffer was added, and the tube was centrifuged at 8,000 rpm for 15 s. RPE buffer was added, and the tube was centrifuged at 8,000 rpm for 2 min, discarding flow-through. To remove the majority of ethanol, the tube was centrifuged again at maximum speed for 1 min. Elution of total RNA was done by placing column in new tube and adding 30 l of DNase/RNase-free water, incubating for 1 min, and centrifuging at 8,000 rpm for 1 min. To maximize yield, the flowthrough was reapplied to the column, and spin was repeated. Total RNA was run on an agarose gel, and the presence of two clear 18S and 28S bands confirmed the integrity of the RNA. Total RNA, integrity, quality, and quantification were assessed by an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA) and a NanoDrop, and all samples had A260/280 ratio of ϳ2.0, indicating "pure" RNA. We used Agilent 2100 expert software to identify samples that met the minimum RNA integrity number of 7.5. Samples were stored at Ϫ80°C until microarray hybridization.
cDNA synthesis. Two micrograms of total RNA from each sample was used to reverse transcribe into cDNA (this was made up to a final volume of 17 l). To this, 1.0 l of random primer (3 g/l) and 1.0 l of dNTP mixture (10 mM each of dNTP) was added and mixed. This was incubated at 65°C for 5 min. The following was added: 6.0 l 5ϫ cDNA synthesis buffer, 3.0 l DTT (0.1 M), 1.0 l RNase out (40 U/l), and 1.0 l Superscript III (200 units/l), giving a final volume of 30 l. This mixture was incubated at room temperature for 5 min, followed by a 3 h incubation at 46°C, mixing, and centrifuging at half-time. A final incubation at 75°C for 15 min was carried out. Finally, the cDNA was diluted 1:10.
Microarray hybridization and experimental design layout. Total RNA samples were not pooled, and each of the 48 RNA samples was labeled with Cy3 (green) fluorescent dye label and separately hybridized to an Agilent bovine expression microarray platform following a previously published protocol (32) . The Agilent platform contains ϳ21,475 probes, printed in duplicate. Of these probes ϳ21,018 are overlapping or close to a bovine gene. The bovine reference sequence contains 25,074 genes, of which ϳ24,137 are unique genes. Of the unique genes, ϳ16,944 are associated with Agilent probes. Issues considered in the experimental design included the availability of biological replicates as well as the quality of the extracted mRNA. The experimental layout was designed to allow a focus on the hormone treatment (treated: ϩsteroid vs. untreated: Ϫsteroid), but also to permit site and genotype contrasts to be carried out (Supplemental Fig. S1 ). Microarrays were hybridized at the SRC Microarray Facility of the Institute for Molecular Biosciences in Brisbane, Australia (http://microarray.imb.uq.edu.au/). Ten different viral polyadenylated RNAs were used as reference "spikes." Fluorescence was measured using the GenePix 4000A scanner (Molecular Devices, Sunnyvale, CA) at a resolution of 10 m. The entire set of expression data corresponding to the 48 hybridizations was deposited to the Gene Expression Omnibus database (http://www.ncbi.nlm.nih.gov/geo/) under accession number GSE25005.
Normalization of microarray data and identification of DE genes. Initial edits discarded 2,210 probes with signal-to-noise (S2N) ratio Ͻ1 in all 48 hybridizations. S2N ratio was calculated by dividing the background corrected intensity by the standard deviation of the background pixels. Prior to normalization, the resulting 1,851,360 intensity readings from 19,265 individual probes were background corrected and base-2 log transformed.
As previously described (45), a combination of ANOVA models and mixtures of distributions were employed to normalize expression signals and to identify DE genes, respectively. In detail, gene expression data normalization was achieved by fitting the following ANOVA mixed-effect model: Yijftmn ϭ ϩ Ai ϩ Gm ϩ AGim ϩ
LGfm ϩ MGjm ϩ TGtm ϩ eijtmn, where Yijkftmn represents the n-th background-adjusted, base-2 log-intensity reading from the i-th array and corresponding to the m-th gene (or Agilent probe) at the t-th hormone treatment (ϩHGP or ϪHGP) taken from an animal raised in the f-th location (NSW or WA) with the j-th marker genotype (1, 2, or 3); is the overall mean; G represents the random gene effects; AG, LG, MG, and TG are the random interaction effects of array ϫ gene, location ϫ gene, marker genotype ϫ gene, and hormone treatment ϫ gene, respectively; and e is the random error term.
Using standard stochastic assumptions, we assumed the effects of G, AG, LG, MG, TG, and e to be independent realizations from a normal distribution with zero mean and between-gene, between-gene within-array, between-gene within-location, between-gene withinmaker genotype, between-gene within-hormone treatment, and within-gene components of variance, respectively. Restricted maximum likelihood estimates of variance components and solutions to model effects were obtained using the analytical gradients option of VCE6 software (ftp://ftp.tzv.fal.de/pub/vce6/). The solutions to the TG effect were used as the normalized mean expression of each gene in each of the conditions under scrutiny. Finally, the difference between the normalized mean expression of a gene in the two hormone treatment conditions was computed as the measure of (possible) differential expression.
Following Ref. 34 , a two-component normal mixture model was fitted to identify DE genes. Parameters of the mixture model were estimated using the EMMIX-GENE software (35) and an estimated experiment-wise false discovery rate (FDR) of Ͻ 1% used as the threshold for determining which genes are DE. The list of DE genes was further scrutinized by only considering those genes with consistent differential expression, i.e., always up-or always downregulated due to the hormone treatment effect and irrespective of the location or marker genotype effect.
qPCR validation. The experimental groups consisted of animals (n ϭ 15) that underwent HGP treatment (87-88 days for NSW site and 48 -49 days for WA site) using the already described Revalor-H treatment. The control animals did not receive these implants (n ϭ 14). Samples were collected, and total RNA was extracted and cDNA synthesized as previously detailed. For the qPCR primers, the details of gene symbols, sequences, and amplicon length are provided in Supplemental Table S1 . Primers for qPCR were designed using Primer 3 ( Supplemental Table S1 ), except for OXT where TaqMan primers were used (assay ID: Bt03217196_g1; Applied Biosystems). Applied Biosystems guarantees that the TaqMan primers amplify the specific target and have no cross-reactivity with other known genes. Primer sequences were blasted against the Bovine assembly and only a pair unique to the gene of interest was used. Where possible, primers were designed across exon/intron boundaries to guard against amplifying genomic DNA. No splice variants were targeted, and therefore exon/intron locations are not applicable.
The qPCR reactions were set up in 96-well plates, one sample per well. Each well contained 10 l SYBR Green, 0.8 l each of forward and reverse primer (10 pmol/l), 6.4 l H 2O, and 2 l cDNA. From each well three aliquots of 5 l were pipetted into wells of a 384-well plate, per sample (technical replicate). Quantitative real-time PCR was carried out using a 7900HT Sequence Detection System (Applied Biosystems).
Specificity of qPCR assays was assessed by single disassociation curves. The PCR efficiencies were calculated per reaction using the linear part of the amplification plots. A calibration curve was not used; instead a general linear model approach was used taking into consideration all CT values ( Supplemental Table S2 ).
Statistical analysis was carried out using SAS software 9.2 (SAS Institute, Cary, NC), using triplicate CT values per sample. This method accounts for "within gene across treatment" and "within treatment across gene" variation and has been used in the past (48, 24, 36) . A general linear model approach was used consisting of the following: Expression (CT) ϳ state ϩ HGP ϩ Animal (state*HGP). This model mimicked the one used for the normalization of microarray expression data. Finally, for each gene, the corresponding contrast of least-square means for CT values in the state by HGP interaction was used to ascertain differential expression.
RIF analysis. To determine which regulatory molecules are likely causal drivers of the muscling phenotype in sex steroid-treated cattle, we undertook RIF analysis (20, 44) , contrasting the regulators against the 8,000 genes (ϳ50% of all the genes represented in the analysis) with most variable expression levels across all 12 experimental conditions (i.e., 2 regional locations ϫ 2 hormone treatments ϫ 3 marker genotypes). This approach generates a ranked list of regulators, reflecting the extent to which they are differentially coexpressed with the abundant, highly DE genes (assumed to contribute most to the phenotype of interest) across the experimental contrast. This network contrast strategy ensured that the DE genes would be captured regardless of the statistical significance threshold and experimental contrast being employed to identify the list of DE genes. Regulators were classified as those genes that encode for proteins that are either transcription factors (TF) or posttranslationally modified (PTM). We obtained the TF by merging the genes in our study with the census previously published (58) . Similarly, the list of PTM was obtained from the Human Protein Reference Database (27) . Overlaying these resulted in 2,944 genes being classified as regulators, of which 836 were TF, 1,820 were PTM, and 288 were both TF and PTM.
Promoter analysis. Promoter analysis was conducted using computational resources provided by Genomatix software suite (http:// www.genomatix.de/). Briefly, promoter sequences were retrieved for the DE genes using Gene2Promoter module. Then, promoter regions were systematically searched for transcription factor binding sites (TFBS) for the estrogen and androgen response elements using MatInspector module (9) . The estrogen response element (ERE) family of TFs contain several related TFs including ER (estrogen receptor, IR3 sites), ERR (estrogen-related receptor) and ESRRB (estrogen-related receptor beta). The androgen response elements (ARE) were members of the glucocorticoid response element family of TFs that include AR (androgen receptor binding sites), GRE (glucocorticoid receptor, IR3 sites), and PRE (progesterone receptor binding sites). In addition, DE genes were examined for sequence conservation (DiAlign TF module) and promoter models (ModelInspector module) across mammals including human, mouse, and pig. Finally, a genome-wide search was conducted to identify all the genes containing putative TFBS for estrogen and ARE in cattle using Gene2Promoter module.
RESULTS

Phenotypic measures.
ADG was significantly increased in the 24 HGP-treated animals vs. the untreated animals (P Ͻ 0.0001), but no significant difference in IMF% was observed ( Table 1) .
Differential expression. The gene expression profile, as inferred from levels of mRNA transcripts in the muscle of cattle, was measured using the bovine Agilent microarray platform. The 19,265 probes (each represented by a unique 60-mer sequence) on this platform had valid signal-to-noise expression ratios across the 48 LD biopsy samples. We identified 121 genes as being consistently DE between steroid-treated and untreated samples (Fig. 1A) .
Five groups of genes hypothesized to respond to steroid treatment were identified ( Table 2 ) and highlighted on Fig. 1B . An increased expression in the LD muscle of steroid-treated animals of a number of genes encoding slow muscle subunits (MYOZ2, MYL6B, and MYL3) was observed. Overall the data support a small increase in slow twitch or slow twitch-like fibers in the LD muscle of steroid-treated animals. Genes encoding the main extracellular matrix collagen proteins (COL1A1, COL1A2, and COL3A1) also exhibited increased expression in the LD muscle of steroid-treated samples. In contrast, a number of genes encoding proteins involved in fat metabolism (including, FABP4, PLIN1, ADIPOQ, TUSC5, and CIDEC) exhibited decreased expression in the LD muscle of steroid-treated animals ( Fig. 1B) . Of the well-studied promyogenic transcription factors and other regulators of muscle mass, such as MYOD1, MYOG, MSTN, FST, IGF1, TH, GH, and DLK1, the only significantly DE genes (increased expression in the LD muscle of steroid-treated animals) were MYOD1 (increased by 1.7-fold) and IGF1 (increased by 1.4fold by array and 2.3-fold by qPCR; Table 3 ).
The detection of biologically important, but subtle, changes in gene expression can be facilitated by overlaying data on top of networks and known biological pathways. Overlaying the differential expression data onto a coexpression network built using bovine LD muscle gene expression data (21) highlighted two modules of genes consistently affected by steroid treatment (Fig. 2) . One module included the fat metabolism genes CIDEC, FABP4, and PLIN1, which exhibited substantially lower expression in the LD muscle of steroid-treated animals, while the other, previously identified as being highly enriched for generic "cell cycle" genes (21), showed subtle, but cocoordinately, increased expression.
By far the most DE gene encodes the precursor of the nonapeptide hormone OXT, being 21-fold higher in the LD muscle of steroid-treated group than in the controls (Fig. 1A) . This result is consistent and uniform at the two different sites and across the tenderness genotypes. This result was confirmed in an independent sample set by a real-time qPCR assay (Table  3 ) that discriminates between the OXT transcript and the very similar vasopressin transcript and which identified a Ͼ97-fold increase in expression of OXT. This very large increase in expression was substantially due to the very low level of expression of the OXT precursor gene in untreated animals. Indeed, the expression of OXT was close to the detection limit of the PCR assay (data not shown), implying normal adult steer cattle muscle expresses OXT at very low levels, or possibly not all. The gene encoding the prepropeptide of the related peptide hormone vasopressin (AVP) was not DE.
Identification of a set of genes directly induced by steroid treatment. Using cluster analysis we identified 32 genes that had a similar or directly opposite expression pattern to OXT ( Fig. 3 ). Of the 32 additional genes, 31 showed increased expression in the LD muscle of steroid-treated animals, while one (CHN1) showed reduced expression. The results for OXT, LMX1B, and MYOZ2 were validated in an independent sample set (n ϭ 30) by qPCR (Table 3) .
Bovine promoter sequences were successfully retrieved for all of the genes except AFF2 and DYNLT1. Human promoter sequences were retrieved for AFF2 and DYNLT1. The promoter sequences were analyzed for the presence of EREs and AREs, up to 1 kb upstream of the transcription start site (Table 4 ). AFF2 and DYNLT1 were analyzed separately, and several EREs and AREs were found. Of the 32 genes in the OXT cluster, 20 and 25 were found to harbor EREs and AREs, respectively (Table 4) . These values indicate a very strong (hypergeometric P value ϭ 4.76e-4) enrichment for EREs and a moderate (P value ϭ 0.0104) enrichment for AREs.
Of the 30 genes that were found to contain an ERE and/or an ARE, three genes encoded transcription factors (LMX1B, SOX8, and BHLHB2). Further promoter analysis revealed that in addition to AREs and EREs, there are potential binding sites for both the LMX1B and SOX8 transcription factors in the promoter region of GREB1.
RIF analysis suggests a causal role for the OXT receptor. The observations above suggest that OXT is a likely mediator of the steroid hormone signal leading to increased muscle growth. However, IGF1, which shows a much smaller, but still significant induction of expression in the LD muscle of steroidtreated animals, is also a good candidate to mediate this effect. There may also be other candidates that are less obvious. To assess the potential contributions of OXT and IGF1 to the muscling phenotype in LD muscle of steroid-treated animals, we used the differential networking approach known as RIF analysis (20) . The ranked RIF list is provided in Supplemental  Table S3 . DE of the regulator is not required for the regulator to receive a high score (Fig. 4) , thus enabling key regulators otherwise hidden in gene expression data to be identified. Regulators with high scores are predicted to be likely to be involved in the generation of the phenotype. Among the 2,944 G Fig. 1 . An MA (M-values/log2 intensity ratios vs. A-values/log2 intensity averages) plot of the normalized gene expression profile. The genes above and below the red line show increased and decreased expression, respectively, in longissimus dorsi (LD) muscle of steroid-treated animals. On the x-axis more abundantly expressed genes (such as the muscle structural subunits) are located toward the right of the figure. A: highlighted in red circles are the consistently differentially expressed genes. B: five groups of candidate genes have been highlighted, and of these the 3 ovals indicate which of these appear to be most strongly affected by the steroid treatment. The full lists of genes included in each group can be found in Table 2 . OXT, oxytocin; ECM, extracellular matrix; HGP, hormone growth promotant. regulators (44) analyzed, 72 were deemed significant (P Ͻ 0.01, Supplemental Table S3 ). The algorithm identified the oxytocin receptor (OXTR) in 12th position, with a similar result obtained irrespective of whether OXT itself was included. Consistent with their presumed role in mediating the effect of the steroids ESR1 (but not ESR2) and AR were also awarded relatively extreme values, albeit not above the significance cut-off, but IGF1R was an average performer ( Fig. 4) .
Dramatic increase in plasma OXT. The level of OXT in the plasma of six steroid-treated and six control animals was measured by immunoassay. Of the 12 animals in which plasma OXT was measured, five of these (4 nontreated and 1 treated) were the same animals in which gene expression was measured for the microarray.
The average level of OXT in the steroid-treated animals was 431.6 Ϯ 189.8 pg/ml 80 days after initial exposure, ϳ50-fold higher than that measured in the controls (8.8 Ϯ 5.5 pg/ml).
Endogenous OXT expression is dramatically increased in late fetal muscle development. To further investigate the pattern of endogenous expression of OXT and OTXR, data from a previous in vivo longitudinal development experiment in fetal bovine LD muscle were re-examined (20, 21, 60) (Fig. 5 ). The expression of OXT showed about a twofold increase above background at day 135 of gestation (coincident with secondary myogenesis) rising to Ͼ128-fold at day 195 (onset of functional differentiation), maintained until birth around day 280 (end of functional differentiation). Very few other genes showed a similar level of increase in expression between days 135 and 195 of fetal development. However, among the 36 other genes showing a greater than eightfold increase in expression across these two time points were the genes encoding four of the eight fast twitch muscle structural proteins included in the analysis, ACNT3, MYH1, MYH2, and MYBPC2. In contrast, genes encoding the six slow twitch subunit genes included in the analysis averaged less than a twofold increase in expression over the same time points.
DISCUSSION
Muscle anabolism. Chronic exposure to the highly androgenic trenbolone acetate and highly estrogenic estradiol sex steroids over 3-4 mo, applied via an implant technology whose release follows a depletion curve observing first-order kinetics (22) , culminated in a 9% increase in bovine carcass weight (8) .
Reflecting the systemic nature of the hormone treatment, the treated cattle (of which the samples in this study is a subset) showed a 10 -12% increase in bone density, as measured by ossification score at slaughter (8) . This result is consistent with that previously reported for estradiol-treated cattle (56) .
A number of DE genes were identified in the skeletal muscle of steroid-treated cattle. The transition to a muscle phenotype favoring the slower subunits has been previously documented in steroid-treated cattle (10) and sheep (12) at the histological level. This is most likely attributable to the androgen component of the hormone implant, given its reported impact on murine quadriceps muscle gene expression (1), although the reverse trend, an increase in fast fibers, has been observed following androgen treatment in aged castrated rat soleus muscle (13) . This may point to either species-, or musclespecific, diversity. We observed a decrease in the expression of a number of fat metabolism-related genes, possibly associated with the trend toward a reduction in intramuscular fat content in the larger dataset (8) , which is a classic response to steroid treatment in a range of mammals including cattle (37) . However, no significant difference in IMF% was observed between the treated and untreated animals in this subset of the larger experiment, probably due to the small sample size. Based on their associated Gene Ontology terms, many of the proteins encoded by the DE fat metabolism-related genes appear to be involved in lipid transport and storage, rather than lipid synthesis or degradation. Therefore we believe that the products of these genes are associated with the intracellular transport and storage of lipids, likely to be associated with the increased bioenergetic demands of higher growth rates (37).
One accepted mechanism by which steroids (especially trenbolone) have been shown to influence protein accretion is by decreasing the rate of protein degradation (22) . Atrogins and the proteasome complex are components that may contribute to protein turnover by affecting the amount of protein degradation. It has been shown that inhibiting atrogin proteolysis prevents skeletal muscle atrophy (30) . Both the atrogins (15) and the proteasomal degradation system (52) have been shown to be regulated at the transcriptional level. However, we found no evidence for the change in expression of either of these two systems in our data set, suggesting that steroid-driven hyper- Fat markers  FABP4, ADIPOQ, CIDEC, TUSC5, PLIN1 (transcript variant 2), PLS1  Extracellular matrix  COL1A1, COL1A2, LOX, COL3A1, DCN  Hormone growth promotant related  AR, ESR1, ESR2, IGF1, IGF1R, CYP1A1, CYP3A5  Fast fiber type subunits  MYH1, TNNT3, MYL1, MYH4, MYOZ1, MYOM2, TMOD4, ACTN3, MYBPC2, TPM1  Slow fiber type subunits  MYL3, MYL2, TNNC1, MYBPC1, TPM3, TNNT1, MYH7B , MYOZ2, MYOM3, MYL6B trophy in this experiment may not occur by reduced protein catabolism. We expected to see molecular signals in the steroid-treated muscle relating to one or more of 1) the classical muscle mass regulators MSTN, TH, IGF1, and GH; 2) the sex steroid receptors AR, ESR1, ESR2, ESRRA, NR3C1, and PGR; and 3) the canonical promyogenic transcription factors MYOD1, MYOG, MYF5, and MYF6. Of these various regulators, only MYOD1 and IGF1 were significantly DE, being 1.7-and 1.4-fold induced, respectively. Welle et al. (61) contrasted the transcriptomes of adult human male and female skeletal muscle with the expectation that sex-steroid biochemistry would dominate their DE list. In fact, there was little evidence for this expectation in their data, supporting our findings.
A promoter analysis searching for androgen and estrogen binding sites 1 kb upstream of the transcription start site of a subset of DE genes (Table 4 ) suggests that they represent a direct primary response to the androgen and estrogen present in the hormone mix, as illustrated in our proposed mechanism in Fig. 6 . Initially, it was believed that OXT expression was directly regulated by the binding of estrogen to ERE in the promoter region (42, 46) . However, this mechanism is now in doubt as the ERE in the promoter of OXT is not a good match to the ERE consensus sequence (51, 29) . Induction of OXT Fig. 2 . Bovine LD muscle "always correlated" landscape (21) . Genes with increased (blue) and decreased (red) expression in LD skeletal muscle of steroid-treated animals overlaid (P Ͻ 0.05). The two magnified areas highlight genes from the cell cycle and fat modules, both of which displayed coordinate differential expression between steroid-treated and control animals. expression by estrogen most likely occurs via an indirect downstream mechanism. The human orthologs of 10 of these genes were previously demonstrated to be DE after 17␤estradiol treatment in a cancer cell line (40) . However, overall, the overlap in DE genes between the present study and other in vivo steroid-treated muscle studies was surprisingly poor. We attribute this to one or more of the following: differences in the steroids used in the treatments, differences in the platforms used to measure gene expression, and differences in comparative physiology i.e., species-specific diversity. For example, in the context of the androgen response, androgen-treated mouse muscle shares only NR4A1 and NPPC in common with the downregulated genes in the current data (13) . Cattle have a low AR density in skeletal muscle, which may account, at a mechanistic level, for their relative unresponsiveness to testosterone compared with other mammals (37) . Currently it is challenging to disentangle the impacts of the treatments and platforms from bona fide species differences.
It is possible that the observed 2.3-fold increase in IGF1 accounts for the 9% increase in carcass weight in sex steroidtreated animals (7) . This mode of action, i.e., via a secondarily induced hormonal signal, has been repeatedly voiced in the growth promotant animal literature, with a particular focus on the possible roles of IGF1, TH, GH, and GHRH (18) . However, several lines of evidence from the current work strongly implicate a surprising alternative, namely the OXT hormone axis.
Induction of OXT expression. The most dramatic finding in sex steroid-treated muscle was the enormous increase in expression of the nonapeptide (9 amino acids) hormone OXT. This was an unexpected result as neurohypophyseal hormone OXT has previous associated functions related to muscle contraction (55, 17, 53) and behavior (2, 39) . OXT is closely related to vasopressin, differing by only two amino acids. However, there was no evidence for differential expression of AVP in this experiment.
Although an interrelationship between sex steroid status and OXT is well established (14) , and skeletal muscle is known to express functional OXTR (6) , the endogenous production of the hormone OXT (albeit induced by artificial exogenous stimulation) by skeletal muscle was unexpected. Steroidtreated animals exhibited plasma values (431.6 Ϯ 189.8 pg/ml) that were upregulated at least ϳ50-fold from the baseline values detected in the controls (8.8 Ϯ 5.5 pg/ml). This change of OXT levels in the plasma in response to the HGP treatment was observed uniformly across animals, regardless of nutrition regime or duration of treatment, consistent with the muscle hypertrophy observed. Since the expression of the OXT gene is significantly increased in the muscle of steroid treated cattle, and as skeletal muscle makes up ϳ50% of body weight, it is likely that much if not all of the circulating OXT is synthesized in the muscle; however, we cannot discount sources from other tissues. The half-life of OXT in the blood is estimated to be ϳ3-4 min (59) . It is possible that the higher levels of circu-lating OXT is due to its half-life being increased, however, since we measured an increased expression of the gene in muscle, increased production is a more plausible and simpler explanation than decreased clearance. In the plasma of steroid-treated animals, we observe about a twofold greater amount of circulating OXT than that observed , where RIF scores are calculated with an algorithm to determine potential regulatory importance. This is to illustrate that genes with extreme RIF scores are not necessarily differentially expressed. For example, oxytocin receptor (OXTR) is not differentially expressed (i.e., lies near the red line in A) but it does receive an extreme RIF1 and RIF2 score. in natural physiological conditions, including extreme transient circumstances such as parturition, where plasma OXT is found only in the ϳ100 -200 pg range (16) . The consistency of plasma concentration between individuals is suggestive of sustained, rather than pulsatile, release.
Treating skeletal myogenic cells in culture with OXT has been shown to induce differentiation, further supporting to the idea that the increased OXT present in LD muscle from steroid-treated animals is involved in the stimulation of muscle growth (38) . From our bovine developmental time course data (31, 60) we observed that the OXT precursor transcript peaked (ϳ128-fold higher) at least 3 mo prior to birth and was sustained perinatally. This timing coincides with secondary myogenesis (increased expression of fast twitch muscle fiber subunits) and subsequent fusion of differentiated myoblasts into myotubes. OXT has also been shown to induce myoblast fusion in cultured human myoblasts (6) . Thus OXT may have a role in the fusion of myoblasts in the late stages of muscle development in the fetus. At all other times, including six further time points taken from adult postmitotic muscle, OXT expression is far lower and possibly insignificant.
OXT in mammalian cardiac muscle and bone development. OXT has been shown to be expressed in vivo in rat cardiac muscle (26) and to be able to induce the differentiation of rat cardiac side population cells into beating cardiomyocytes in vitro (41) . According to Jankowski et al. (25) , OXT also plays a significant in vivo role in rodent cardiac ontogeny. They detected the highest OXT levels in late-gestation embryos and the first few days postnatally when cardiac myocytes are intensely hyperplastic (25) , in line with our observations in skeletal muscle. They also observed that circulating OXT is higher in newborn rats than adults (25) and that OXT expression in rat brain is low prior to birth. Janskowski et al. (25) interpreted the heart as being the main source of fetal and newborn circulating OXT. Since skeletal muscle accounts for close to 50% of total mammalian body mass (19) while cardiac muscle is Ͻ1%, our observations suggest that skeletal, rather than cardiac, muscle is likely to represent the major source of circulating OXT in pre-and perinatal mammals. Recently, Tamma et al. (54) created an OXT null mouse and discovered it yields a surprising phenotype of osteoporosis. Based on a range of experiments (54) , they concluded that OXT is a novel anabolic bone hormone capable of directly regulating bone mass, which exerts its effect on bone phenotype by stimulating both osteoblast differentiation and osteoclast formation. Given this role, it seems very likely that the increase in bone mass observed in steroid-treated cattle (57) is a product of circulating OXT produced by the muscle.
Model for the mechanism of the anabolic action of steroid hormones in cattle LD muscle. Estrogen and androgen bind to intracellular receptors, which in turn bind to promoter regions of specific genes (see Table 4 ) to either induce or repress expression of the primary response to steroid treatment (Fig.  6 ). Two genes in the primary response themselves encode transcription factors (LMX1B and SOX8), and our results indicate that they may bind to the promoter region of GREB1 (a classic estrogen-induced gene), which may also form part of the secondary response ( Fig. 6 ). However, muscle is composed of a mixture of cell types, which are likely to respond differently to the exposure to steroids. As part of the secondary response a group of fat metabolism genes are downregulated via an unknown mechanism, which may simply reflect a decrease in the lipid storage activity of intramuscular adipocytes due to the increased bio-energetic demand of supporting enhanced muscle growth (Fig. 6 ). Also as part of the secondary response a group of genes encoding collagen subunits is up regulated by an unknown mechanism, probably in the mature muscle cells. It is most likely that the increase in cell cycle gene expression occurs in the muscle satellite cells, as differentiated muscle cells do not divide and the activity of adipocytes storing lipid is decreased, which is not consistent with increased cell numbers. The twofold increase in the expression of the diagnostic satellite cell marker SOX8 (49) also supports the increased proliferation of satellite cells.
The small increase in expression of IGF1 and WISP2, which it binds to, is consistent with IGF1 playing a role in the increase in muscle growth. However, the RIF analysis more strongly supports OXTR than the IGF1 receptor IGF1R, as a key driver in the phenotype induced by the steroid treatment. The signaling cascade downstream of the receptor remains somewhat enigmatic. The increase in expression of MYOD1 is also consistent with an increased number of muscle cells in the late stages of differentiation and biased toward slow twitch type muscle fibers.
Based on the experiments described here a much more comprehensive and more detailed picture is now available of the mechanisms by which the steroid treatment of cattle leads to the observed phenotypes of increased average daily gain. Furthermore, future studies should evaluate the association between increased OXT levels and other traits related to HGP treatment including increased bone density, increased meat toughness, and reduced intramuscular fat content (7, 8) . It is likely that these mechanisms will be at least partially applicable across the mammals. However, there are still many gaps in our understanding, not the least of which is, does OXT alone have an anabolic activity?
